Literature DB >> 24922678

How to improve the outcome in patients with AJCC stage I hepatocellular carcinoma.

Anthony Q Yap1, Carlos A Millan1, Jing-Houng Wang2, Chih-Chi Wang3, Sen-Nan Lu2, Shih-Ho Wang1, Chih-Che Lin1, Yueh-Wei Liu1, Chee-Chien Yong1, Wei-Feng Li1, Ting-Lung Lin1, Chao-Long Chen1.   

Abstract

AIM: Survival of patients with stage I hepatocellular carcinoma (HCC) is higher than in patients with more advanced disease, however many of them will ultimately die of tumor recurrence and liver failure. Our objective focuses on identifying the pathological and clinical factors that could affect disease-free (DFS) and overall survival (OS). In addition we reviewed the treatment offered for recurrence and its impact on OS. PATIENTS AND METHODS: Between January 1992 and December 2002, a total of 473 patients who underwent hepatectomy for HCC at the Kaohsiung Chang Gung Memorial Hospital were enrolled in this study. Relevant clinicopathological and perioperative variables were subjected to univariate and multivariate analysis.
RESULTS: A total of 224 patients with a mean follow-up period of 4.6 years were analyzed. The 1-, 3-, 5-, and 10-year DFS rates were 82.5%, 57.6%, 46.9% and 32.0% respectively. The 1-, 3-, 5-, and 10-year OS rates were 91.5%, 83.0%, 70.1% and 56.3% respectively. The multivariate analysis identified age >50 years, Indocyanine Green (ICG) clearance test and cirrhosis as independent factors that negatively impact DFS and age ≥ 50 years, resection type, presence of complications and tumor recurrence as factors affecting OS. In patients with recurrence (n=130), the factors that negatively impact OS were blood transfusion, age ≥ 50, blood loss and presence of surgical complications.
CONCLUSION: Meticulous surgical technique is the key to improving the outcome of patients with stage I HCC. The presence of complications was the only modifiable clinicopathological factor that affected the OS in our study. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; clinical; disease-free survival; overall survival; pathological; surgical

Mesh:

Year:  2014        PMID: 24922678

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.

Authors:  Yi-Chia Chan; Catherine S Kabiling; Vinod G Pillai; Gustavo Aguilar; Chih-Chi Wang; Chao-Long Chen
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

2.  Is partial hepatectomy a curable treatment option for hepatocellular carcinoma accompanied by cirrhosis? A meta-analysis and cure model analysis.

Authors:  Byungje Bae; Keera Kang; Sung Kyu Song; Chul-Woon Chung; Yongkeun Park
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.